BioCentury
ARTICLE | Clinical News

ProstVac: Ph I/II started

April 20, 2017 9:50 PM UTC

Bavarian Nordic said NCI investigators began an open-label, U.S. Phase I/II trial to evaluate ProstVac plus Opdivo nivolumab and Yervoy ipilimumab in about 65 patients. The Phase I portion will enroll...